We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Novartis AG | NYSE:NVS | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.07 | -0.07% | 97.27 | 97.91 | 97.07 | 97.75 | 1,045,674 | 01:00:00 |
From May 2019 to May 2024
By Colin Kellaher
Biogen Inc. and its Samsung Bioepis Co. venture on Tuesday said the European Medicines Agency accepted their marketing authorization application for SB11, a proposed biosimilar to Roche Holdings AG's blockbuster eye drugs Lucentis.
Biosimilars are near-copies of biologic drugs that are made from living cells and are analogous to generic copies of traditional pill-form medicines. If approved, SB11 would join a growing number of biosimilars developed by Samsung Bioepis, a joint venture between Biogen and Samsung BioLogics Co., and commercialized by Biogen.
Lucentis was developed by Roche's Genentech unit and is marketed in Europe by Novartis AG. The European patent on Lucentis expires in 2022.
Last November, Biogen and Samsung Bioepis said they agreed to pursue ophthalmology biosimilar candidates for Lucentis and Regeneron Pharmaceuticals Inc.'s Eylea.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
October 06, 2020 08:25 ET (12:25 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Novartis Chart |
1 Month Novartis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
